Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Siemens Showcases Broad Portfolio of Infectious Disease Testing Capabilities at ECCMID 2012

Published: Monday, April 16, 2012
Last Updated: Monday, April 16, 2012
Bookmark and Share
Company exhibit featured the latest in liver health, microbiology and molecular diagnostic solutions.

Siemens Healthcare Diagnostics has showcased its broad portfolio of infectious disease testing capabilities¹ — from screening and diagnosis to susceptibility testing, genotyping, therapy selection and monitoring — at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London. The Siemens solutions on display at ECCMID 2012 reinforced the company's commitment to the development of reliable, high-quality infectious disease diagnostic solutions to help laboratories optimise workflow and enhance operational efficiency.

The exhibit — themed “Innovation. Powered for Infectious Disease Solutions.”— featured innovative products designed to address the current and growing demands of infectious disease testing, including customised workflow options, assays to help clinicians improve patient care, and clinically-validated, expert-based software solutions that support personalised medicine.

“Infectious disease is a leading cause of death worldwide2, making it critical that clinicians have access to diagnostic solutions that provide trustworthy results, which ultimately contribute to optimal patient outcomes,” said Christoph Gauer, PhD, CEO, Molecular and Microbiology Business Segment at Siemens Healthcare Diagnostics. “Visitors to our ECCMID booth learnt how Siemens can help them improve the delivery of vital information healthcare providers require to care for their patients impacted by infectious disease.”

Liver Health Solutions

The Siemens ECCMID exhibit provided a platform to showcase the company’s portfolio of diagnostic solutions for managing liver-disease patients, including routine chemistry tests, hepatitis serology assays, viral load testing and ultrasound systems. A key highlight was the recently launched ADVIA Centaur® ELF™ Test3, the first routine standardised direct biomarker panel for the assessment of liver fibrosis, a leading indicator of chronic liver disease, such as cirrhosis and liver cancer. With results provided in about an hour, the ELF test combines three serum biomarkers—hyaluronic acid (HA), Procollagen III amino terminal peptide (PIIINP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)—which provide a score, shown to correlate to the level of liver fibrosis as assessed by liver biopsy. In an international multi-centre study with a mix of patient groups, the ELF test was clinically validated and found to be accurate to differentiate mild, moderate and severe fibrosis4.

Microbiology Solutions

Attendees also learnt about Siemens’ latest microbiology offerings, including LabPro Connect, a new software solution that consolidates databases for multiple testing systems. The open-system configuration option delivers workstation networking by aggregating LabPro ID/AST data to bench and laboratory office computers, reducing wasted staff time absorbed by visiting different instruments to collect information. LabPro Connect can also be configured as a closed-system without workstation networking.

Also highlighted were microbiology automation and mass spectrometry solutions now available from Siemens as a result of a recently forged strategic partnership with Copan and co-marketing agreement with Bruker Corporation. The Copan Walk-Away Specimen Processor (WASP® instrument)5 offers fully automated bacteriology specimen processing, individualised sample management, utilising familiar streaking patterns, standardises workflow processes and optimises specimen set-up activities to free up staff resources. The Bruker MALDI Biotyper6 provides faster, more accurate and very cost-effective molecular microorganism identification using MALDI-TOF mass spectrometry for proteomic fingerprinting. This technology provides faster TTR, along with outstanding accuracy and sensitivity, to meet the demands of diverse laboratory needs.

Molecular Solutions

Additionally, Siemens’ ECCMID booth included information about the VERSANT® HCV RNA 1.0 Assay, a highly sensitive viral load assay for the VERSANT kPCR Molecular System7. This assay aids in the management of individuals infected with hepatitis C (HCV)—one of the main causes of chronic liver disease worldwide8— who are undergoing antiviral therapy. This assay provides outstanding precision across the dynamic range and 100% specificity with a 95% lower confidence limit of 99.7%, and features technology that is compatible with all HCV genotypes.

Visitors also found out about TRUGENE® HIV-1 GuideLines™ 17.09, the latest interpretive algorithm for HIV-1 drug resistance, which are clinically validated and updated annually by an independent expert panel, as well as the company’s latest tissue preparation and extraction solutions to maximise lab efficiency.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!